Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13505903 | 0.73 | GPR35 (0.35) | — | |
| SCHEMBL8502218 | 0.72 | MAPT (0.48) | CYP2A6MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1453289 | 0.70 | HTR1B (0.40) | CYP2A6ALDH1A1SMN1; SMN2SLC6A4GAA | |
| SCHEMBL3789614 | 0.70 | CYP2A6 (0.58) | CYP2A6MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1453412 | 0.70 | ALDH1A1 (0.31) | CYP2A6MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL368354 | 0.69 | CYP2A6 (0.56) | CYP2A6MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL9347729 | 0.68 | CYP2A6 (0.55) | CYP2A6MAPTALDH1A1SMN1; SMN2SLC6A4 | |
| SCHEMBL9347766 | 0.68 | CYP2A6 (0.55) | CYP2A6MAPTALDH1A1SMN1; SMN2SLC6A4 | |
| SCHEMBL1028769 | 0.68 | — | — | |
| SCHEMBL6036190 | 0.67 | ALDH1A1 (0.33) | ALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558571-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037775-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-5276024-A | 3-substituted cephalosporins, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0487996-A2 | Cephalosporins substituted in position 3, process for their preparation and their use as medicine | BAYER AG (DE) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287393-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | CYP2A6 295/4885MAPT 3498/4885ALDH1A1 862/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | CYP2A6 295/4885MAPT 3498/4885ALDH1A1 862/4885 |
| US-20050080115-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | CYP2A6 295/4885MAPT 3498/4885ALDH1A1 862/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | CYP2A6 295/4885MAPT 3498/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.